Results 221 to 230 of about 8,158 (292)

Impact of Prolonged Fasting and Refeeding on Enteroendocrine Hormone Expression: One More Piece of the Fasting/Refeeding Metabolic Puzzle. [PDF]

Biomedicines
Nunes G, Guimarães M, Oliveira SB, Pereira SS, Vara-Luiz F, Mendes I, Palma C, Oliveira C, Fonseca J.   +8 more
europepmc   +1 more source

Fatty Pancreas and Risk of Type 2 Diabetes, Chronic Kidney Disease and Cardiovascular Events: Evidence From a Population‐Based Cohort

United European Gastroenterology Journal, Volume 14, Issue 6, July 2026.
ABSTRACT Background Fatty pancreas is a metabolically active ectopic fat depot, but its cardiometabolic implications have been assessed using heterogeneous thresholds. We investigated the association of fatty pancreas, quantified using MRI‐derived proton density fat fraction (PDFF) and categorised according to 2026 international consensus thresholds ...
Nicola Pugliese, Oveis Jamialahmadi, Arturo Cesaro, Valentina Flagiello, Rosellina M. Mancina, Alessio Aghemo, Stefano Romeo   +6 more
wiley   +1 more source

Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction. [PDF]

J Diabetes Investig
Ohkuma T, Aotani R, Sakamoto W, Oshiro A, Ago T.   +4 more
europepmc   +1 more source

Real‐World vs. Randomized Trial Evidence for Incretin‐Based Therapies: A Narrative Review

Journal of Diabetes, Volume 18, Issue 7, July 2026.
RCTs of incretin‐based treatment show effective weight loss and glycemic benefit, as well as improved CV outcomes. There is, however, uncertainty as to whether the RCTs translate to real‐world outcomes. This narrative review suggests real‐world outcomes are comparable to RCTs after accounting for submaximal dosing and high discontinuation rates ...
Zachary Bloomgarden
wiley   +1 more source

Glucagon-Like Peptide-1 Is Prognostic of Mortality in Acute Respiratory Failure. [PDF]

Crit Care Explor
Hansell CE, Aneis HA, Kitsios GD, Bain WG, Zhao Y, Suber TL, Evankovich JW, Sharma L, Ramakrishnan SK, Prendergast NT, Hensley MK, Malik S, Petro N, Patel JJ, Nouraie SM, Dela Cruz CS, Zhang Y, McVerry BJ, Shah FA.   +18 more
europepmc   +1 more source

Incretins and SGLT-2 inhibitors in diabetic patients with neuroendocrine tumors: current updates and future directions. [PDF]

Rev Endocr Metab Disord
Ruggeri RM, Grossrubatscher EM, Ciocca E, Hasballa I, Jaafar S, Oldani M, Rubino M, Russo F, Isidori AM, Colao A, Faggiano A, NIKE group.   +11 more
europepmc   +1 more source

Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5761-5766, July 2026.
ABSTRACT Aims To characterize the cardiometabolic profiles of oral and subcutaneous glucagon‐like peptide‐1 (GLP‐1) receptor mono‐agonists in adults with overweight or obesity, with or without type 2 diabetes (T2D), using network meta‐analysis (NMA).
Ying Lu, Jiajie Chen, Yuqing Guo, Hao Ding, Yu‐Lun Liu, Michelle A. Van Name, Mona Sharifi, Yuan Lu, Yong Chen   +8 more
wiley   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5767-5778, July 2026.
ABSTRACT Aims To investigate the association between use of GLP‐1 receptor agonists and incident Parkinson's disease. Material and Methods Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active‐comparator, new‐user design.
Arvid Engström, Henrik Svanström, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Peter Ueda, Björn Pasternak   +10 more
wiley   +1 more source

JNK3 regulates β cell responses to incretins in human islets and mouse models. [PDF]

J Clin Invest
Louzada RA, Gonzalez Medina M, Pita-Grisanti V, Bouviere J, Neves AF, Almaça J, Han MS, Davis RJ, Leibowitz G, Blandino-Rosano M, Bernal-Mizrachi E.   +10 more
europepmc   +1 more source

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6162-6171, July 2026.
ABSTRACT Aims Tirzepatide, an injectable glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist (RA), is approved for weight management in several regions. Oral GLP‐1 RAs, such as semaglutide, are under investigation to improve convenience, acceptance and adherence versus injectable formulations ...
Andreea Ciudin, Erin Johansson, Sarah Zimner‐Rapuch, Georgios K. Dimitriadis, Mathias Hempfling, Laura J. Clark, Ludi Fan, Helene Sapin   +7 more
wiley   +1 more source